Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $4

Benzinga · 05/12/2025 14:17
Barclays analyst Peter Lawson maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target from $5 to $4.